Paget's disease of bone: diagnosis and treatment update

Current rheumatology reports

Volumn 2, Issue 1, 2000, Pages 67-73

  Noor, Mustafa ^a,b   Shoback, Dolores ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Biostatistics   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN;

CLINICAL TRIAL; FEMALE; HOSPITALIZATION; HUMAN; MALE; METABOLISM; OSTEOCLAST; PAGET BONE DISEASE; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

CALCITONIN; CLINICAL TRIALS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEITIS DEFORMANS; OSTEOCLASTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0034139356     PISSN: 15233774     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11926-996-0071-x     Document Type: Review

References (53)

1. 1. J Paget 1877 On a form of chronic inflammation of bones (osteitis deformans) Med-Chir Transactions of London 60 37 64 Paget J: On a form of chronic inflammation of bones (osteitis deformans). Med-Chir Transactions of London 1877, 60:37–64.
2. 2. FS Kaplan 1992 Paget’s disease of bone: exploring the questions Calcified Tissue Intern 51 1 3 10.1007/BF00296206 1:STN:280:DyaK3s%2FgslCisw%3D%3D Kaplan FS: Paget’s disease of bone: exploring the questions. Calcified Tissue Intern 1992, 51:1–3.
3. 3. PB Guyer AT Chamberlain 1980 Paget’s disease of bone in two American cities BMJ 280 985 985 7417771 10.1136/bmj.280.6219.985 1:STN:280:DyaL3M%2Fit1agug%3D%3D Guyer PB, Chamberlain AT: Paget’s disease of bone in two American cities. BMJ 1980, 280:985.
4. 4. ES Siris 1994 Epidemiological aspects of Paget’s disease: family history and relationship to other medical conditions Seminars Arthritis Rheum 23 222 225 10.1016/0049-0172(94)90037-X 1:STN:280:DyaK2c3nvVGjtQ%3D%3D Siris ES: Epidemiological aspects of Paget’s disease: family history and relationship to other medical conditions. Seminars Arthritis Rheum 1994, 23:222–225.
5. 5. JA Kanis 1991 Pathophysiology and treatment of paget’s disease of bone Dunitz London Kanis JA: Pathophysiology and treatment of paget’s disease of bone. London: Dunitz, 1991.
6. 6. H Jaffe 1933 Paget’s disease of bone Arch Pathol 15 83 83 1:CAS:528:DyaA3sXisVSgtQ%3D%3D Jaffe H: Paget’s disease of bone: Arch Pathol 1933, 15:83.
7. 7. JM Mirra EW Brien J Tehranzadeh 1995 Paget’s disease of bone: review with emphasis on radiologic features, Part I Skeletal Radiol 24 163 71 7610408 1:STN:280:DyaK2MzjsVOntg%3D%3D A thorough review of the spectrum of radiographic findings in Paget’s disease in 2 parts Mirra JM, Brien EW, Tehranzadeh J: Paget’s disease of bone: review with emphasis on radiologic features, Part I. Skeletal Radiol 1995, 24:163–71. A thorough review of the spectrum of radiographic findings in Paget’s disease in 2 parts.
8. 8. BS Epstein JA Epstein 1969 The association of cerebellar tonsillar herniation with basilar impression incident to Paget’s disease Am J Roentgenol, Rad Therapy Nucl Med 107 535 542 1:STN:280:DyaE3c%2Fls12jsA%3D%3D Epstein BS, Epstein JA: The association of cerebellar tonsillar herniation with basilar impression incident to Paget’s disease. Am J Roentgenol, Rad Therapy Nucl Med 1969, 107:535–542.
9. 9. ES Sadar RJ Walton H Gossman 1972 Neurological dysfunction in Paget’s disease of the vertebral column J Neurosurg 37 661 665 4511088 10.3171/jns.1972.37.6.0661 1:STN:280:DyaE3s7ivFKrtg%3D%3D Sadar ES, Walton RJ, Gossman H: Neurological dysfunction in Paget’s disease of the vertebral column. J Neurosurg 1972, 37:661–665.
10. 10. MR Wick GP Siegal KK Unni 1981 Sarcomas of bone complicating osteitis deformans Paget’s disease: fifty years’ experience Am J Surg Pathol 5 47 59 6941703 1:STN:280:DyaL3M3ivF2qsg%3D%3D 10.1097/00000478-198101000-00008 Wick MR, Siegal GP, Unni KK, et al.: Sarcomas of bone complicating osteitis deformans Paget’s disease: fifty years’ experience. Am J Surg Pathol 1981, 5:47–59.
11. 11. JM Mirra EW Brien J Tehranzadeh 1995 Paget’s disease of bone: review with emphasis on radiologic features, Part II Skeletal Radiol 24 173 184 7610409 1:STN:280:DyaK2MzjsVOntw%3D%3D A thorough review of the spectrum of radiographic findings in Paget’s disease in 2 parts Mirra JM, Brien EW, Tehranzadeh J: Paget’s disease of bone: review with emphasis on radiologic features, Part II. Skeletal Radiol 1995, 24:173–184. A thorough review of the spectrum of radiographic findings in Paget’s disease in 2 parts.
12. 12. L Alvarez N Guaanabens P Peris 1995 Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget’s disease J Bone Miner Res 10 458 465 7785468 1:STN:280:DyaK2MzgsV2rtQ%3D%3D Alvarez L, Guaanabens N, Peris P, et al.: Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget’s disease. J Bone Miner Res 1995, 10:458–465.
13. 13. ES Siris TP Clemens D McMahon 1989 Parathyroid function in Paget’s disease of bone J Bone Min Res 4 75 79 1:STN:280:DyaL1M3ksVaktQ%3D%3D Siris ES, Clemens TP, McMahon D, et al.: Parathyroid function in Paget’s disease of bone. J Bone Min Res 1989, 4:75–79.
14. 14. YW Bahk YH Park SK Chung JG Chi 1995 Bone pathologic correlation of multimodality imaging in Paget’s disease J Nucl Med 36 1421 1426 7629588 1:STN:280:DyaK2MzlsF2gtg%3D%3D Bahk YW, Park YH, Chung SK, Chi JG: Bone pathologic correlation of multimodality imaging in Paget’s disease. J Nucl Med 1995, 36:1421–1426.
15. 15. GA Kaufmann M Sundaram DJ McDonald 1991 Magnetic resonance imaging in symptomatic Paget’s disease Skeletal Radiology 20 413 418 1925672 10.1007/BF00191082 1:STN:280:DyaK38%2Fit1KrsQ%3D%3D Kaufmann GA, Sundaram M, McDonald DJ: Magnetic resonance imaging in symptomatic Paget’s disease. Skeletal Radiology 1991, 20:413–418.
16. 16. DJ Barker PW Clough PB Guyer MJ Gardner 1977 Paget’s disease of bone in 14 British towns BMJ 1 1181 1183 861530 10.1136/bmj.1.6070.1181 1:STN:280:DyaE2s7ot1OqtQ%3D%3D Barker DJ, Clough PW, Guyer PB, Gardner MJ: Paget’s disease of bone in 14 British towns. BMJ 1977, 1:1181–1183.
17. 17. FM Detheridge PB Guyer DJ Barker 1982 European distribution of Paget’s disease of bone BMJ Clinical Research Ed. 285 1005 1008 10.1136/bmj.285.6347.1005 1:STN:280:DyaL3s%2FisVSjsA%3D%3D Detheridge FM, Guyer PB, Barker DJ: European distribution of Paget’s disease of bone. BMJ Clinical Research Ed. 1982, 285:1005–1008.
18. 18. FM Detheridge DJ Barker PB Guyer 1983 Paget’s disease of bone in Ireland BMJ Clinical Research Ed. 287 1345 1346 10.1136/bmj.287.6402.1345 1:STN:280:DyaL2c%2FlsVSrsQ%3D%3D Detheridge FM, Barker DJ, Guyer PB: Paget’s disease of bone in Ireland. BMJ Clinical Research Ed. 1983, 287:1345–1346.
19. 19. DJ Barker 1984 The epidemiology of Paget’s disease of bone BM Bulletin 40 396 400 1:STN:280:DyaL2M7nsFyitg%3D%3D Barker DJ: The epidemiology of Paget’s disease of bone. BM Bulletin 1984, 40:396–400.
20. 20. Y Ishikawa H Tsukuma RW Miller 1996 Low rates of Paget’s disease of bone and osteosarcoma in elderly Japanese Lancet 347 1559 1559 8684133 10.1016/S0140-6736(96)90714-X 1:STN:280:DyaK283ivVWltg%3D%3D Ishikawa Y, Tsukuma H, Miller RW: Low rates of Paget’s disease of bone and osteosarcoma in elderly Japanese. Lancet 1996, 347:1559.
21. 21. SE Papapoulos 1997 Paget’s disease of bone: clinical, pathogenetic and therapeutic aspects Baillieres Clin Endocrinol Metab 11 117 143 9222489 10.1016/S0950-351X(97)80553-8 1:STN:280:DyaK2szmsFKlsA%3D%3D A general overview of Paget’s disease with emphasis on newer therapeutic modalities. Clearly written with ample references to the primary sources Papapoulos SE: Paget’s disease of bone: clinical, pathogenetic and therapeutic aspects. Baillieres Clin Endocrinol Metab 1997, 11:117–143. A general overview of Paget’s disease with emphasis on newer therapeutic modalities. Clearly written with ample references to the primary sources.
22. 22. BG Mills FR Singer 1976 Nuclear inclusions in Paget’s disease of bone Science 194 201 202 959849 10.1126/science.959849 1:STN:280:DyaE283ntFWltg%3D%3D Mills BG, Singer FR: Nuclear inclusions in Paget’s disease of bone. Science 1976, 194:201–202.
23. 23. MT Gordon SC Bell AP Mee 1993 Prevalence of canine distemper antibodies in the pagetic population J Med Virol 40 313 317 8228922 10.1002/jmv.1890400409 1:STN:280:DyaK2c%2FksFGksg%3D%3D Gordon MT, Bell SC, Mee AP, et al.: Prevalence of canine distemper antibodies in the pagetic population. J Med Virol 1993, 40:313–317.
24. 24. MT Gordon AP Mee DC Anderson PT Sharpe 1992 Canine distemper virus transcripts sequenced from pagetic bone Bone Mineral 19 159 174 10.1016/0169-6009(92)90923-2 1:CAS:528:DyaK3sXht1ahu74%3D Gordon MT, Mee AP, Anderson DC, Sharpe PT: Canine distemper virus transcripts sequenced from pagetic bone. Bone Mineral 1992, 19:159–174.
25. 25. SV Reddy FR Singer L Mallette GD Roodman 1996 Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget’s disease J Bone Miner Res 11 1602 1607 8915767 1:CAS:528:DyaK28XnsVyqs7g%3D 10.1002/jbmr.5650111103 Reddy SV, Singer FR, Mallette L, Roodman GD: Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget’s disease. J Bone Miner Res 1996, 11:1602–1607.
26. 26. C Cooper E Dennison S Kellingray 1999 The epidemiology of Paget’s disease in Britain: is the prevalence decreasing? J Bone Min Res 14 2 192 197 10.1359/jbmr.1999.14.2.192 1:STN:280:DyaK1M7jt1Gnsg%3D%3D This study reports recent epidemiologic trends in the prevalence of Paget’s disease in England showing a decline in incidence and severity of illness Cooper C, Dennison E, Kellingray S, et al.: The epidemiology of Paget’s disease in Britain: is the prevalence decreasing? J Bone Min Res 1999 Feb, 14 (2):192–197. This study reports recent epidemiologic trends in the prevalence of Paget’s disease in England showing a decline in incidence and severity of illness.
27. 27. T Cundy K McAnulty D Wattie 1997 Evidence for secular change in Paget’s disease Bone 20 69 71 8988350 10.1016/S8756-3282(96)00310-9 1:STN:280:DyaK2s7kt1WitA%3D%3D This paper reports recent epidemiologic trends in the prevalence of Paget’s disease. The 5-year prevalence data from 1973–1978 and 1998–1993 from a referral clinic in Auckland, New Zealand are presented. A decline in both incidence and severity (as measured by biochemical and radiographic findings) of Paget’s disease was noted Cundy T, McAnulty K, Wattie D, et al.: Evidence for secular change in Paget’s disease. Bone 1997, 20:69–71. This paper reports recent epidemiologic trends in the prevalence of Paget’s disease. The 5-year prevalence data from 1973–1978 and 1998–1993 from a referral clinic in Auckland, New Zealand are presented. A decline in both incidence and severity (as measured by biochemical and radiographic findings) of Paget’s disease was noted.
28. 28. AA Morales-Piga JS Rey-Rey J Corres-Gonzaalez 1995 Frequency and characteristics of familial aggregation of Paget’s disease of bone J Bone Mineral Res 10 663 670 1:STN:280:DyaK2MzjsFeiug%3D%3D Morales-Piga AA, Rey-Rey JS, Corres-Gonzaalez J, et al.: Frequency and characteristics of familial aggregation of Paget’s disease of bone. J Bone Mineral Res 1995, 10:663–670.
29. 29. JD Cody FR Singer GD Roodman 1997 Genetic linkage of Paget disease of the bone to chromosome 18q Am J Hum Genet 61 1117 1122 9345096 10.1086/301601 1:CAS:528:DyaK2sXns1yju78%3D One of the first reports of genetic linkage of Paget’s disease to chromosome 18 near the region where the genes for familial expansile osteolysis are located Cody JD, Singer FR, Roodman GD, et al.: Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 1997, 61:1117–1122. One of the first reports of genetic linkage of Paget’s disease to chromosome 18 near the region where the genes for familial expansile osteolysis are located.
30. 30. SI Haslam W Hul Van A Morales-Piga 1998 Paget’s disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity J Bone Miner Res 13 911 917 9626621 10.1359/jbmr.1998.13.6.911 1:STN:280:DyaK1c3ovF2hsQ%3D%3D Most recent paper on genetic susceptibility to Paget’s disease. The authors studied the relationship between the 18q21-22 locus and Paget’s disease in eight large multiplex families from diverse ethnic backgrounds with inherited Paget’s disease. Paget’s disease was inherited as an autosomal dominant trait in all families, with high penetrance by the sixth decade Haslam SI, Van Hul W, Morales-Piga A, et al.: Paget’s disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 1998, 13:911–917. Most recent paper on genetic susceptibility to Paget’s disease. The authors studied the relationship between the 18q21-22 locus and Paget’s disease in eight large multiplex families from diverse ethnic backgrounds with inherited Paget’s disease. Paget’s disease was inherited as an autosomal dominant trait in all families, with high penetrance by the sixth decade.
31. 31. Wuyts W, Balemans W, Morales-Piga A, et al.: Towards the identification of a second gene locus predisposing to Paget’s disease, Second Joint Meeting of the American Society for Bone and Mineral Research and The International Bone and Mineral Society (Abstract), San Francisco, CA, 1998:S545.
32. 32. GD Roodman 1995 Osteoclast function in Paget’s disease and multiple myeloma Bone 17 57S 61S 8579899 10.1016/8756-3282(95)00179-H 1:CAS:528:DyaK2MXns1OgsLg%3D Roodman GD: Osteoclast function in Paget’s disease and multiple myeloma. Bone 1995, 17:57S-61S.
33. 33. D Chappard N Retailleau-Gaborit R Filmon 1998 Increased nucleolar organizer regions in osteoclast nuclei of Paget’s bone disease Bone 22 45 49 9836854 10.1016/S8756-3282(97)00226-3 1:STN:280:DyaK1c7gtVWltA%3D%3D Chappard D, Retailleau-Gaborit N, Filmon R, et al.: Increased nucleolar organizer regions in osteoclast nuclei of Paget’s bone disease. Bone 1998, 22:45–49.
34. 34. GD Roodman 1996 Advances in bone biology: the osteoclast Endocrin Rev 17 308 332 1:CAS:528:DyaK28Xltl2mtrY%3D An excellent review of cellular and molecular advances in osteoclast biology, outlining the current state of research Roodman GD: Advances in bone biology: the osteoclast. Endocrin Rev 1996, 17:308–332. An excellent review of cellular and molecular advances in osteoclast biology, outlining the current state of research.
35. 35. E Jimi T Shuto T Koga 1995 Macrophage colony-stimulating factor and interleukin-1 alpha maintain the survival of osteoclastlike cells Endocrinology 136 808 811 7835314 10.1210/en.136.2.808 1:CAS:528:DyaK2MXjtleiu7c%3D Jimi E, Shuto T, Koga T: Macrophage colony-stimulating factor and interleukin-1 alpha maintain the survival of osteoclastlike cells. Endocrinology 1995, 136:808–811.
36. 36. JA Hoyland AJ Freemont PT Sharpe 1994 Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget’s disease J Bone Miner Res 9 75 80 8154312 1:STN:280:DyaK2c3gsFequw%3D%3D Hoyland JA, Freemont AJ, Sharpe PT: Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget’s disease. J Bone Miner Res 1994, 9:75–80.
37. 37. GD Roodman 1996 Paget’s disease and osteoclast biology Bone 19 209 212 8873960 10.1016/8756-3282(96)00211-6 1:STN:280:DyaK2s%2FislyksQ%3D%3D Roodman GD: Paget’s disease and osteoclast biology. Bone 1996, 19:209–212.
38. 38. AP Mee JA Hoyland P Baird 1995 Canine bone marrow cell cultures infected with canine distemper virus: an in vitro model of Paget’s disease Bone 17 461S 466S 8579953 10.1016/8756-3282(95)00140-9 1:STN:280:DyaK287hvFahug%3D%3D Mee AP, Hoyland JA, Baird P, et al.: Canine bone marrow cell cultures infected with canine distemper virus: an in vitro model of Paget’s disease. Bone 1995, 17:461S-466S.
39. 39. GD Roodman N Kurihara Y Ohsaki 1992 Interleukin 6: a potential autocrine/paracrine factor in Paget’s disease of bone J Clin Invest 89 46 52 1729280 10.1172/JCI115584 1:CAS:528:DyaK38XlslahsA%3D%3D Roodman GD, Kurihara N, Ohsaki Y, et al.: Interleukin 6: a potential autocrine/paracrine factor in Paget’s disease of bone. J Clin Invest 1992, 89:46–52.
40. 40. VM Natale WJ Filho AJS Duarte 1997 Cellular immunity aspects in elderly subjects with Paget’s disease of bone Calcif Tissue Int 60 410 414 9115156 10.1007/s002239900254 1:CAS:528:DyaK2sXivVejtrk%3D Natale VM, Filho WJ, Duarte AJS: Cellular immunity aspects in elderly subjects with Paget’s disease of bone. Calcif Tissue Int 1997, 60:410–414.
41. 41. AS Alam A Gallagher V Shankar 1992 Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption Endocrinology 130 3617 3624 1597159 10.1210/en.130.6.3617 1:CAS:528:DyaK38XksVWgtb4%3D Alam AS, Gallagher A, Shankar V, et al.: Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology 1992, 130:3617–3624.
42. 42. R Tarquini F Perfetto B Tarquini 1998 Endothelin-1 and Paget’s bone disease: is there a link Calcif Tissue Int 63 118 120 9685515 10.1007/s002239900500 1:CAS:528:DyaK1cXkvFWmsbc%3D Tarquini R, Perfetto F, Tarquini B: Endothelin-1 and Paget’s bone disease: is there a link ? Calcif Tissue Int 1998, 63:118–120.
43. 43. SJ Choi RD Devlin C Menaa 1998 Cloning and identification of human Sca as a novel inhibitor of osteoclast formation and bone resorption J Clin Invest 102 1360 1368 9769328 10.1172/JCI2667 1:CAS:528:DyaK1cXmsFOrsrk%3D Report of osteoclast inhibitory factor a new class of factors that selectively inhibit osteoclast funtion in vivo Choi SJ, Devlin RD, Menaa C, et al.: Cloning and identification of human Sca as a novel inhibitor of osteoclast formation and bone resorption. J Clin Invest 1998, 102:1360–1368. Report of osteoclast inhibitory factor a new class of factors that selectively inhibit osteoclast funtion in vivo.
44. 44. PD Delmas PJ Meunier 1997 The management of Paget’s disease of bone N Engl J Med 336 558 566 9023094 10.1056/NEJM199702203360807 1:STN:280:DyaK2s7msVOgtQ%3D%3D A concise authoritative review of the currently available therapeutic agents for Paget’s disease Delmas PD, Meunier PJ: The management of Paget’s disease of bone. N Engl J Med 1997, 336:558–566. A concise authoritative review of the currently available therapeutic agents for Paget’s disease.
45. 45. FR Singer RS Fredericks C Minkin 1980 Salmon calcitonin therapy for Paget’s disease of bone. The problem of acquired clinical resistance Arthr Rheum 23 1148 1154 10.1002/art.1780231012 1:STN:280:DyaL3M%2FjvV2gsg%3D%3D Singer FR, Fredericks RS, Minkin C: Salmon calcitonin therapy for Paget’s disease of bone. The problem of acquired clinical resistance. Arthr Rheum 1980, 23:1148–1154.
46. 46. GA Rodan 1998 Mechanisms of action of bisphosphonates Ann Rev Pharmacol Toxicol 38 375 388 10.1146/annurev.pharmtox.38.1.375 1:CAS:528:DyaK1cXivF2iurk%3D This paper is a general overview of bisphosphonates and their cellular and molecular modes of action Rodan GA: Mechanisms of action of bisphosphonates. Ann Rev Pharmacol Toxicol 1998, 38:375–388. This paper is a general overview of bisphosphonates and their cellular and molecular modes of action.
47. 47. H Fleisch 1997 Bisphosphonates in bone disease: from the laboratory to the patient Parthenon Publishing Group New York Fleisch H: Bisphosphonates in bone disease: from the laboratory to the patient. New York: Parthenon Publishing Group; 1997.
48. 48. S Papapoulos 1996 Bisphosphonates: pharmacology and use in the treatment of osteoporosis R Marcus D Feldman J Kelsey Osteoporsis Academic Press New York Papapoulos S: Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In Osteoporsis. Edited by Marcus R, Feldman D, Kelsey J. New York: Academic Press, 1996.
49. 49. E Siris RS Weinstein R Altman 1996 Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone J Clin Endocrinol Metab 81 961 967 8772558 10.1210/jc.81.3.961 1:CAS:528:DyaK28Xhs1agsrk%3D Siris E, Weinstein RS, Altman R, et al.: Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab 1996, 81:961–967.
50. 50. ES Siris AA Chines RD Altman 1998 Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study J Bone Miner Res 13 1032 1038 9626635 10.1359/jbmr.1998.13.6.1032 1:CAS:528:DyaK1cXjvFSmur8%3D Siris ES, Chines AA, Altman RD, et al.: Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res 1998, 13:1032–1038.
51. 51. FR Singer TL Clemens RA Eusebio PJ Bekker 1998 Risedronate, a highly effective oral agent in the treatment of patients with severe Paget’s disease J Clin Endocrinol Metab 83 1906 1910 9626117 10.1210/jc.83.6.1906 1:CAS:528:DyaK1cXjslCgtLY%3D Singer FR, Clemens TL, Eusebio RA, Bekker PJ: Risedronate, a highly effective oral agent in the treatment of patients with severe Paget’s disease. J Clin Endocrinol Metab 1998, 83:1906–1910.
52. 52. WD Fraser TC Stamp RA Creek 1997 A double-blind, multicentre, placebo-controlled study of tiludronate in Paget’s disease of bone Postgrad Med J 3 496 502 10.1136/pgmj.73.862.496 Fraser WD, Stamp TC, Creek RA, et al.: A double-blind, multicentre, placebo-controlled study of tiludronate in Paget’s disease of bone. Postgrad Med J 1997, 3:496–502.
53. 53. AJ Coukell A Markham 1998 Pamidronate: A review of its use in the management of osteolytic bone metastases, tumourinduced hypercalcaemia and Paget’s disease of bone Drugs Aging 12 149 168 9509293 10.2165/00002512-199812020-00007 1:CAS:528:DyaK1cXhsFCjtLs%3D Coukell AJ, Markham A. Pamidronate: A review of its use in the management of osteolytic bone metastases, tumourinduced hypercalcaemia and Paget’s disease of bone. Drugs Aging 1998, 12:149–168.